$ABT

5 theses

bullish 60%neutral 0%bearish 40%

Avg return (3d)

+0.7%

Win rate (3d)

60% (5 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Nov 13, 4:45 PM ET

$ABTSEC Form 4bearish

Moreland Mary K · EXECUTIVE VICE PRESIDENT at ABBOTT LABORATORIES · 8d agono track record yet

Sold 3,500 @ $116.00 avg · $406,000 · 2026-11-05

Form 4: Moreland Mary K sold ABT

Moreland Mary K (EXECUTIVE VICE PRESIDENT at ABBOTT LABORATORIES) reported an open-market sale of 3,500 shares of ABT at an average $116.00, roughly $406,000, in a Form 4 filed 2026-11-06.

At post $109.93Now $108.52-1.3% since postedas of Nov 13, 4:45 PM ET

1d—

3d+0.5%

1w-1.3%

1m—

3m—

6m—

1y—

View filing on SEC.gov →

$ABTSEC Form 4bearish

Morrone Louis H. · EXECUTIVE VICE PRESIDENT at ABBOTT LABORATORIES · 93d agono track record yet

Sold 5,850 @ $109.83 avg · $642,506 · 2026-08-11

Form 4: Morrone Louis H. sold ABT

Morrone Louis H. (EXECUTIVE VICE PRESIDENT at ABBOTT LABORATORIES) reported an open-market sale of 5,850 shares of ABT at an average $109.83, roughly $642,506, in a Form 4 filed 2026-08-13.

At post $110.59Now $108.52-1.9% since postedas of Nov 13, 4:45 PM ET

1d-0.0%

3d-0.0%

1w+2.6%

1m-8.9%

3m-1.2%

6m—

1y—

View filing on SEC.gov →

$ABTr/ValueInvestingDiscussionbullish

u/Idntevncare · 100d ago8 prior · 100% at 3mo

HEALTHCARE is a great value right now

Abbott Laboratories is positioned as a value play in the healthcare sector, with structural growth from aging demographics and potential AI applications in life-saving products.

At post $107.30Now $108.52+1.1% since postedas of Nov 13, 4:45 PM ET

1d-0.1%

3d-0.1%

1w+3.1%

1m+0.3%

3m+7.7%

6m—

1y—

original post →

$ABTr/ValueInvestingIndustry/Sectorbullish

u/raytoei · 113d ago39 prior · 61% at 3mo

Medical-Device Stocks Are in the Bargain Bin. 6 to Buy - Barron’s

Abbott has posted stronger margins and is launching new devices for arrhythmias and diabetes monitoring, with analyst price targets implying 15% upside. Medical-device valuations at 20-30% discounts to the S&P 500 with 5-6% free-cash-flow yields offer compelling entry points as sector fears prove overblown.

At post $103.85Now $108.52+4.5% since postedas of Nov 13, 4:45 PM ET

1d—

3d+2.7%

1w+1.2%

1m+11.7%

3m-0.1%

6m—

1y—

original post →

$ABTr/ValueInvestingStock Analysisbullish

u/raytoei · 182d ago39 prior · 61% at 3mo

10 Quality Stocks That Hit New Lows This Week—and Look Like Bargains - Barron’s

Abbott fell 32% this year after weak infant formula results and an Exact Sciences acquisition write-down, but now offers value at 15x 2026 earnings. The diversified portfolio shows resiliency, and the company could return to 10%-plus earnings growth in 2027.

At post $86.75Now $108.52+25.1% since postedas of Nov 13, 4:45 PM ET

1d—

3d+0.5%

1w-0.6%

1m+3.1%

3m+27.5%

6m+25.1%

1y—

original post →

End of results.